U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C27H27N9O6S
Molecular Weight 605.625
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TEZOSENTAN

SMILES

COC1=CC=CC=C1OC2=C(OCCO)N=C(N=C2NS(=O)(=O)C3=NC=C(C=C3)C(C)C)C4=CC(=NC=C4)C5=NN=NN5

InChI

InChIKey=TUYWTLTWNJOZNY-UHFFFAOYSA-N
InChI=1S/C27H27N9O6S/c1-16(2)18-8-9-22(29-15-18)43(38,39)34-26-23(42-21-7-5-4-6-20(21)40-3)27(41-13-12-37)31-24(30-26)17-10-11-28-19(14-17)25-32-35-36-33-25/h4-11,14-16,37H,12-13H2,1-3H3,(H,30,31,34)(H,32,33,35,36)

HIDE SMILES / InChI
Molecular Formula C27H27N9O6S
Molecular Weight 605.625
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Unknown
86413
Substance Class Chemical
Created
by admin
on Sat Dec 16 17:06:08 UTC 2023
Edited
by admin
on Sat Dec 16 17:06:08 UTC 2023
Record UNII
64J9J55263
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TEZOSENTAN
INN   MART.   MI   VANDF  
INN  
Official Name English
ACT-050089
Code English
TEZOSENTAN [VANDF]
Common Name English
tezosentan [INN]
Common Name English
TEZOSENTAN [MI]
Common Name English
TEZOSENTAN [MART.]
Common Name English
N-(6-(2-HYDROXYETHOXY)-5-(O-METHOXYPHENOXY)-2-(2-(1H-TETRAZOL-5-YL)-4-PYRIDYL)-4-PYRIMIDINYL)-5-ISOPROPYL-2-PYRIDINESULFONAMIDE
Common Name English
Code System Code Type Description
NCI_THESAURUS
C97358
Created by admin on Sat Dec 16 17:06:09 UTC 2023 , Edited by admin on Sat Dec 16 17:06:09 UTC 2023
PRIMARY
CAS
180384-57-0
Created by admin on Sat Dec 16 17:06:09 UTC 2023 , Edited by admin on Sat Dec 16 17:06:09 UTC 2023
PRIMARY
SMS_ID
100000091247
Created by admin on Sat Dec 16 17:06:09 UTC 2023 , Edited by admin on Sat Dec 16 17:06:09 UTC 2023
PRIMARY
EPA CompTox
DTXSID20170956
Created by admin on Sat Dec 16 17:06:09 UTC 2023 , Edited by admin on Sat Dec 16 17:06:09 UTC 2023
PRIMARY
FDA UNII
64J9J55263
Created by admin on Sat Dec 16 17:06:09 UTC 2023 , Edited by admin on Sat Dec 16 17:06:09 UTC 2023
PRIMARY
EVMPD
SUB25782
Created by admin on Sat Dec 16 17:06:09 UTC 2023 , Edited by admin on Sat Dec 16 17:06:09 UTC 2023
PRIMARY
ChEMBL
CHEMBL61780
Created by admin on Sat Dec 16 17:06:09 UTC 2023 , Edited by admin on Sat Dec 16 17:06:09 UTC 2023
PRIMARY
DRUG BANK
DB06558
Created by admin on Sat Dec 16 17:06:09 UTC 2023 , Edited by admin on Sat Dec 16 17:06:09 UTC 2023
PRIMARY
MESH
C120582
Created by admin on Sat Dec 16 17:06:09 UTC 2023 , Edited by admin on Sat Dec 16 17:06:09 UTC 2023
PRIMARY
MERCK INDEX
m10670
Created by admin on Sat Dec 16 17:06:09 UTC 2023 , Edited by admin on Sat Dec 16 17:06:09 UTC 2023
PRIMARY Merck Index
PUBCHEM
151174
Created by admin on Sat Dec 16 17:06:09 UTC 2023 , Edited by admin on Sat Dec 16 17:06:09 UTC 2023
PRIMARY
WIKIPEDIA
Tezosentan
Created by admin on Sat Dec 16 17:06:09 UTC 2023 , Edited by admin on Sat Dec 16 17:06:09 UTC 2023
PRIMARY
INN
7846
Created by admin on Sat Dec 16 17:06:09 UTC 2023 , Edited by admin on Sat Dec 16 17:06:09 UTC 2023
PRIMARY
Related Record Type Details
Structure of TEZOSENTAN DISODIUM
SALT/SOLVATE -> PARENT
ENDOTHELIN B RECEPTOR
TARGET -> INHIBITOR
ENDOTHELIN-1 RECEPTOR
TARGET -> INHIBITOR
Related Record Type Details
Structure of TEZOSENTAN
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966